NewYork-Presbyterian Queens, stylized as NewYork-Presbyterian/Queens (NYP/Q or NYP/Queens), is a not-for-profit acute care and teaching hospital in the Flushing neighborhood of Queens in New York City. Formerly operating as Booth Memorial Hospital and New York Hospital Queens (NYHQ), it is located on the northeast corner of Main Street and Booth Memorial Avenue.The hospital was formed in 1892 as the Rescue Home for Women, becoming known as Booth Memorial Hospital in 1919. The current Queens campus opened in 1957. The NewYork–Presbyterian Healthcare System had assumed control of the Booth Memorial Hospital until 2015, when the NewYork–Presbyterian Hospital, headquartered in Manhattan, assumed control and made the Booth Memorial Hospital a Queens campus.
Penetrating or fistulizing Crohn's disease (CD) has been considered one of "end" phenotypes. CD-associated fistula can be classified based on the etiology, location, source and target organs, length, depth, and concurrent inflammation or stricture. While the majority of CD-associated fistulas can be detected by cross-sectional imaging and contrasted small bowel series or colon enema, endoscopy can provide useful information on concurrent inflammation or stricture and, sometimes, help identify primary and secondary orifices of fistula. In selected patients, therapy may be delivered via endoscopy, such as balloon dilation or stricturotomy of concurrent strictures, and fistulotomy of short, superficial fistula.
Assessment of disease activity in inflammatory bowel disease and surveillance of colitis-associated neoplasia has benefited from advances in image-enhanced endoscopy. Confocal laser endomicroscopy (CLE) and endocytoscopy allow for real-time visualization of cellular architecture details of the gastrointestinal tract, further defining endoscopic mucosal healing or mild disease activity and guiding targeted biopsy for the disease monitoring as well as dysplasia surveillance. CLE and endocytoscopy are valid tools for both structural and functional assessment of the intestinal epithelium. CLE or endocytoscopy has even been proposed as a tool for optical biopsy. Magnification endoscopy equipped with the latest models of white-light endoscopy can highlight the mucosal structure and subepithelial microvasculature, especially in combined use with dye-based chromoendoscopy or narrow-band imaging. Optical coherence tomography has been used for the assessment of disrupted layered structures of bowel wall in the differential diagnosis between Crohn's disease and ulcerative colitis. We expect that the development of probe-based ultrasound elastography will help the distinction between inflammatory and fibrotic strictures.
Background: Voltage and activation maps localize the region of the critical isthmus in most atrial tachycardia (AT) ablations, but identification of the specific ablation target within that region remains subject to operator interpretation. Hypothesis: A deep-learning model trained on the electroanatomic map (EAM) can automate critical-isthmus localization during AT ablation and generalize across mapping platforms. Methods: A deep-learning model was trained to localize the critical isthmus from EAMs in 83 scar-related AT ablation cases mapped on either Abbott EnSite or Biosense CARTO, in a retrospective, two-center cohort. The reference standard was the critical isthmus of the induced rhythm, labeled on each EAM by consensus of three board-certified electrophysiologists. Performance was assessed by 10-fold cross-validation, with the primary endpoint defined as localization within 5mm. Results: A single model performed similarly on EnSite and CARTO mapping systems. The model correctly localized the critical isthmus to within 5mm in 45% and within 10mm in 58%; the top-ranked prediction fell within the labeled isthmus in 37%. Median localization error was 6.4mm. Performance was comparable between EnSite (n=33, median 6.3mm, Fig. A) and CARTO (n=50, median 7.1mm, Fig. B). Region-level F1 was 0.41 (95% CI 0.35-0.48) and AUPRC 0.34 (95% CI 0.27-0.42) across the 10 folds. Our institution's prior graph convolutional network reported a median localization error of 7.3mm on a smaller cohort (n=29). Model predictions were focused, covering a median of 3.6 times the labeled isthmus area. Conclusion: The model can serve as an intraprocedural “second reader” that narrows the operator's search for the critical isthmus, complementing expert mapping. Diffuse predictions in a subset of cases remain a limitation. When validated in external and prospective cohorts, automated identification of the critical isthmus may shorten mapping time and support more consistent targeting during AT ablation.
Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for more than 18, 000 cases each year within the United States. While roughly 60% of patients with DLBCL achieve durable remissions with existing chemotherapies, the prognosis of patients with refractory DLBCL is poor. The immune landscape of DLBCL is complex and further elucidation of the interplay between T cell activation and immunosuppression within the tumor microenvironment (TME) is necessary in order to better stratify patients and predict outcomes for therapy. This complexity, as well as the relevance of the spatial context of the various cell types within the TME necessitate the ability to simultaneously visualize biomarkers and phenotypic markers via multiplex immunohistochemical (mIHC) assays. Here, we construct a 12-plex SignalStar mIHC panel consisting of T cell phenotypic, activation and suppression markers in order to characterize the TME of FFPE DLBCL cores. We visualize immuno-oncology markers in the context of the tumor and myeloid cells, as defined by CD68. In this assay, all 12 antibodies are applied in one primary incubation, followed by the addition of a network of fluorescently-labeled oligonucleotides used to amplify the signal of 4 antibody-oligo conjugates across 3 rounds of imaging. Following amplification and imaging of the first 4 conjugates, the fluorescent signal was enzymatically removed and the process repeated for two more rounds. The three resulting images were then aligned using Visiopharm’s TissuealignTM platoform. Quantitative analysis, including positive cell counts and marker co-localization, was conducted with Visiopharm’s PhenoplexTM. Biomarker expression patterns were also examined using PhenoplexTM. Finally, we correlated these data with patient demographics, disease progression, and treatment responses. Our data demonstrate that the SignalStar mIHC assay is a powerful tool in the elucidation of the complex immunosuppressive TME, enabling researchers to better understand the responses to immunotherapeutic approaches and chemotherapy combination strategies. Jennifer Ziello, Shuling Zhang, Derek Papalegis, Lily Vu, Gabriella Spang, Jean Loebelenz, Arvin Ruiz, Giorgio Inghirami, Sarah Klein. Spatial analysis of the DLBCL tumor microenvironment via the novel SignalStarTM multiplex immunohistochemistry assay [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 772.
